Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study

• Published in: Journal of clinical oncology Vol. 37; no. 4; pp. 269 - 277
• Main Authors: Kater, Arnon P., Seymour, John F., Hillmen, Peter, Eichhorst, Barbara, Langerak, Anton W., Owen, Carolyn, Verdugo, Maria, Wu, Jenny, Punnoose, Elizabeth A., Jiang, Yanwen, Wang, Jue, Boyer, Michelle, Humphrey, Kathryn, Mobasher, Mehrdad, Kipps, Thomas J.
• Format: Journal Article
• Language: English
• Published: United States 01.02.2019
• Subjects: Aged; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Bendamustine Hydrochloride - administration & dosage; Bendamustine Hydrochloride - adverse effects; Bridged Bicyclo Compounds, Heterocyclic - administration & dosage; Bridged Bicyclo Compounds, Heterocyclic - adverse effects; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy; Leukemia, Lymphocytic, Chronic, B-Cell - mortality; Leukemia, Lymphocytic, Chronic, B-Cell - pathology; Male; Middle Aged; Neoplasm, Residual; Progression-Free Survival; Recurrence; Rituximab - administration & dosage; Rituximab - adverse effects; Sulfonamides - administration & dosage; Sulfonamides - adverse effects; Time Factors

The MURANO study demonstrated significant progression-free survival (PFS) benefit for fixed-duration venetoclax-rituximab compared with bendamustine-rituximab in relapsed/refractory chronic lymphocytic leukemia. With all patients off treatment, we report minimal residual disease (MRD) kinetics and u...